Kirenol
产品说明书
 |
同义名 : | 奇壬醇 |
| CAS号 : | 52659-56-0 | |
| 货号 : | A449892 | |
| 分子式 : | C20H34O4 | |
| 纯度 : | 98% | |
| 分子量 : | 338.48 | |
| MDL号 : | MFCD00210519 | |
| 存储条件： |
Pure form Sealed in dry, room temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Kirenol is isolated from ethanolic extract of Siegesbeckia orientalis with anti-inflammatory and analgesic activity. The anti-inflammatory effect of kirenol 0.4 - 0.5% (w/w) was similar to the effect of piroxicam gel 4h after carrageenan injection[3]. Kirenol treatment significantly decreased high glucose-induced cardiofibroblasts proliferation and increased the cardiomyocytes viability, prevented the loss of mitochondrial membrane potential and further attenuated cardiomyocytes apoptosis, accompanied by a reduction in apoptosis-related protein expression. Kirenol gavage could affect the expression of pro-inflammatory cytokines in a dose-dependent manner but not lower lipid profiles, and only decrease fasting plasma glucose, fasting plasma insulin and mean HbA1c levels in high-dose kirenol-treated group at some time-points[4]. Kirenol inhibited the migration, invasion, and proinflammatory of IL-6 secretion of RA-associated synovial fibroblasts (FLS) at a concentration of 100 - 200 μg/ml in vitro. Proinflammatory cytokines production and synovium hyperplasia and cartilage erosion were also inhibited in a collagen-induced arthritis (CIA) mouse model upon kirenol treatment[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.95mL 0.59mL 0.30mL |
14.77mL 2.95mL 1.48mL |
29.54mL 5.91mL 2.95mL |
| 参考文献 |
|---|